Rhythm Pharmaceuticals Inc (RYTM)

$110.47 +1.35 (1.24%)
Market Cap 7.25B
Revenue (ttm) 130.13M
Net Income (ttm) -260.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.26%
Debt to Equity Ratio 0.00
Volume 356,000
Avg Vol 582,778
Day's Range N/A - N/A
Shares Out 66.42M
Stochastic %K 75%
Beta 2.12
Analysts Strong Sell
Price Target $118.00

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 264 4280
Fax: 857 264 4299
Address:
222 Berkeley Street, 12th Floor, Boston, United States
profitraider
profitraider Oct. 23 at 11:54 PM
$RYTM Listen, I told you long ago that this was going to happen, but you didn’t want to listen… and, all I got was being laughed at!
2 · Reply
biolover
biolover Oct. 23 at 1:11 AM
$VKTX $NVO Sema price will not be $150 / month. It is hard to imagine by what mechanism the admin will enforce that. And this indirectly means $LLY demise , which committed $50 B for manufacturing. Most compounders sell for $200. $RYTM $SLNO sell wt loss drugs for BWS in the range of $500 k to $1 M annually ( outrageous ) Regardless what Trump stated ( his $150 is like the 1000% drop ) both Lilly and novo can rely on cash pay and not even care about Medicare. Novo clear # 1 problem is coming up with something competitive with tirzepatide more than anything else. Look at the growth rate of both drugs. This is an informed customers segment
2 · Reply
TeeMan123
TeeMan123 Oct. 22 at 4:42 PM
$RYTM never trust mgmt blindly… but when it comes to David Meeker you have to trust the guy until he gives you a reason not too… he sees something in pws, he has long history of never just starting a trial on a whim.. trust the process
0 · Reply
abcdzepeda
abcdzepeda Oct. 21 at 11:14 PM
$RYTM RYTM is reporting earnings on November 4, hopefully they use this day to give us the data on PWS. 
2 · Reply
TeeMan123
TeeMan123 Oct. 21 at 4:45 PM
$RYTM I have no idea why we are having a bear raid, safe to assume it has to do with pws positioning… but in moments like this it feels great to David Meeker at the helm who executes and doesn’t mess around.
1 · Reply
S_Franconi
S_Franconi Oct. 21 at 3:51 PM
$CELC $RVMD $IRON $RYTM
0 · Reply
judgeyoung2
judgeyoung2 Oct. 20 at 9:06 PM
$RYTM Disclose preliminary results from the Company’s setmelanotide Phase 2 trial in Prader-Willi syndrome in the second half of 2025;
0 · Reply
abcdzepeda
abcdzepeda Oct. 20 at 5:23 PM
$RYTM
0 · Reply
TeeMan123
TeeMan123 Oct. 18 at 3:59 PM
$RYTM with strong pws data.. this company fetches $210 in a buyout
1 · Reply
TeeMan123
TeeMan123 Oct. 18 at 3:42 PM
$RYTM if they had enough data to make dramatic changes to the trial design (multi center/52 week trial); why didn’t they simply report out the data they promised the street?? Finalizing M&A discussions???
0 · Reply
Latest News on RYTM
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 21, 2025, 4:01 PM EDT - 4 days ago

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Rhythm Pharmaceuticals, Inc. - Special Call

Sep 24, 2025, 5:07 PM EDT - 4 weeks ago

Rhythm Pharmaceuticals, Inc. - Special Call

Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 2:04 PM EDT - 6 weeks ago

Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 2 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Aug 20, 2025, 4:01 PM EDT - 2 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 5:26 PM EDT - 2 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Jul 22, 2025, 4:01 PM EDT - 3 months ago

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Jul 12, 2025, 6:00 PM EDT - 3 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Jul 10, 2025, 3:39 PM EDT - 3 months ago

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Jul 10, 2025, 6:21 AM EDT - 3 months ago

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Jul 9, 2025, 4:16 PM EDT - 3 months ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Jul 8, 2025, 4:01 PM EDT - 3 months ago

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

Jun 30, 2025, 11:00 AM EDT - 4 months ago

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

Jun 25, 2025, 8:00 AM EDT - 4 months ago

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

May 14, 2025, 8:00 AM EDT - 5 months ago

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript

May 7, 2025, 3:21 PM EDT - 6 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

May 7, 2025, 7:00 AM EDT - 6 months ago

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 6 months ago

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Apr 8, 2025, 1:38 PM EDT - 7 months ago

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Apr 7, 2025, 7:11 AM EDT - 7 months ago

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Apr 7, 2025, 7:00 AM EDT - 7 months ago

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Apr 6, 2025, 12:00 PM EDT - 7 months ago

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Mar 31, 2025, 2:05 PM EDT - 7 months ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI ALNY VRTX XENE

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Mar 20, 2025, 4:01 PM EDT - 7 months ago

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Mar 19, 2025, 4:01 PM EDT - 7 months ago

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Mar 18, 2025, 7:00 AM EDT - 7 months ago

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 1:46 PM EST - 8 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 26, 2025, 7:00 AM EST - 8 months ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25, 2025, 11:21 AM EST - 8 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Feb 13, 2025, 8:00 AM EST - 9 months ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Jan 10, 2025, 7:15 AM EST - 10 months ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Dec 20, 2024, 2:24 PM EST - 11 months ago

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Dec 20, 2024, 2:15 PM EST - 11 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Dec 3, 2024, 6:00 AM EST - 11 months ago

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Nov 18, 2024, 7:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Nov 13, 2024, 6:30 PM EST - 1 year ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Nov 13, 2024, 4:01 PM EST - 1 year ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 10:45 PM EST - 1 year ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Nov 5, 2024, 4:01 PM EST - 1 year ago

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Nov 4, 2024, 4:01 PM EST - 1 year ago

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Oct 24, 2024, 6:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22, 2024, 7:36 AM EDT - 1 year ago

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29, 2024, 9:30 AM EDT - 1 year ago

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Aug 26, 2024, 8:02 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Three Biotech Stocks to Buy for the "Golden Age of Medicine"

Aug 19, 2024, 1:49 PM EDT - 1 year ago

Three Biotech Stocks to Buy for the "Golden Age of Medicine"

LLY SNY

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 11:22 AM EDT - 1 year ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Jul 31, 2024, 9:10 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

profitraider
profitraider Oct. 23 at 11:54 PM
$RYTM Listen, I told you long ago that this was going to happen, but you didn’t want to listen… and, all I got was being laughed at!
2 · Reply
biolover
biolover Oct. 23 at 1:11 AM
$VKTX $NVO Sema price will not be $150 / month. It is hard to imagine by what mechanism the admin will enforce that. And this indirectly means $LLY demise , which committed $50 B for manufacturing. Most compounders sell for $200. $RYTM $SLNO sell wt loss drugs for BWS in the range of $500 k to $1 M annually ( outrageous ) Regardless what Trump stated ( his $150 is like the 1000% drop ) both Lilly and novo can rely on cash pay and not even care about Medicare. Novo clear # 1 problem is coming up with something competitive with tirzepatide more than anything else. Look at the growth rate of both drugs. This is an informed customers segment
2 · Reply
TeeMan123
TeeMan123 Oct. 22 at 4:42 PM
$RYTM never trust mgmt blindly… but when it comes to David Meeker you have to trust the guy until he gives you a reason not too… he sees something in pws, he has long history of never just starting a trial on a whim.. trust the process
0 · Reply
abcdzepeda
abcdzepeda Oct. 21 at 11:14 PM
$RYTM RYTM is reporting earnings on November 4, hopefully they use this day to give us the data on PWS. 
2 · Reply
TeeMan123
TeeMan123 Oct. 21 at 4:45 PM
$RYTM I have no idea why we are having a bear raid, safe to assume it has to do with pws positioning… but in moments like this it feels great to David Meeker at the helm who executes and doesn’t mess around.
1 · Reply
S_Franconi
S_Franconi Oct. 21 at 3:51 PM
$CELC $RVMD $IRON $RYTM
0 · Reply
judgeyoung2
judgeyoung2 Oct. 20 at 9:06 PM
$RYTM Disclose preliminary results from the Company’s setmelanotide Phase 2 trial in Prader-Willi syndrome in the second half of 2025;
0 · Reply
abcdzepeda
abcdzepeda Oct. 20 at 5:23 PM
$RYTM
0 · Reply
TeeMan123
TeeMan123 Oct. 18 at 3:59 PM
$RYTM with strong pws data.. this company fetches $210 in a buyout
1 · Reply
TeeMan123
TeeMan123 Oct. 18 at 3:42 PM
$RYTM if they had enough data to make dramatic changes to the trial design (multi center/52 week trial); why didn’t they simply report out the data they promised the street?? Finalizing M&A discussions???
0 · Reply
abcdzepeda
abcdzepeda Oct. 18 at 2:55 AM
$RYTM
1 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 5:21 PM
Goldman Sachs has updated their rating for Rhythm Pharmaceuticals ( $RYTM ) to Buy with a price target of 139.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 17 at 10:26 AM
WATCHLIST OCT 17 2025 $VHC VirnetX Holding Wins General Services Administration Multiple Award Schedule Contract; Contract Expands Federal Access To Secure Communications And Zero-Trust Cybersecurity Solutions $CTSH Cognizant Expands AI Services Portfolio With Enterprise Vibe Coding Blueprint To Drive Enterprise-Wide Transformation $GNL Global Net Lease Upgraded To Investment Grade By Fitch To BBB- From BB+, Backed By $3B Asset Dispositions (Including $1.8B Retail Sale) And August 2025 Revolving Credit Refinance $RYTM Morgan Stanley Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $129 $KZR Kezar Life Sciences Initiates Strategic Alternatives Review, Announces Workforce Restructuring And Rights Plan Extension After FDA Blocks Path Forward For Zetomipzomib In Autoimmune Hepatitis; Reports $90.2M Cash Balance
0 · Reply
abcdzepeda
abcdzepeda Oct. 16 at 8:04 PM
$RYTM we closed green on a sea of red day, I will take that! 
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 6:01 PM
Morgan Stanley has adjusted their stance on Rhythm Pharmaceuticals ( $RYTM ), setting the rating to Overweight with a target price of 122 → 129.
0 · Reply
Metrobilly
Metrobilly Oct. 16 at 3:30 PM
$RYTM Plus 277%. Like this stock!
0 · Reply
MaverikIT
MaverikIT Oct. 16 at 2:16 PM
@IsabellaDC @TheLongVol $PRAX - massive Holy $GRAL $VKTX getting into the $RYTM
0 · Reply
InvestorWisdom
InvestorWisdom Oct. 16 at 2:57 AM
$SPRO chart: Relative strength is increasing + MAs are aligned and curving up… the volume on this chart is distorted because of that one spike, but it’s slowly picking up the past 7 days. It just needs a volume spike to accelerate the trend… and it could happen soon with this attractive setup. This chart is calling traders to the playground Also, biotech stocks are heating up. $IBB & $XBI (biotech ETFs) just hit the highest price since 2022 this week…. And my other biotechs holdings like $RYTM are $INSM are strong This sector is also one of the biggest beneficiaries of AI progress …
0 · Reply
TeeMan123
TeeMan123 Oct. 16 at 2:06 AM
$RYTM EXTREMELY BULLISH IMO
0 · Reply
TeeMan123
TeeMan123 Oct. 16 at 1:53 AM
$RYTM holy smokes… the company updated the trial design for pws on clinical trials. org, adjusting the trial design to multi center and extending duration to 52 weeks, one would think you don’t make a trial bigger/longer if their isn’t an obvious signal being seen 🤔 !!!!!!!!!!!
1 · Reply
Doozio
Doozio Oct. 15 at 11:35 PM
🐒🍌🧠 $ZYME ♾️ is in $RYTM in its PRIM
0 · Reply
Metrobilly
Metrobilly Oct. 15 at 4:32 PM
$RYTM How do I post a picture of a rocket ship?
1 · Reply